Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients receiving mepolizumab vs. placebo had a smaller ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

Please provide your email address to receive an email when new articles are posted on . Risk for first moderate/severe COPD exacerbation was lower among dry powder vs. metered-dose or soft mist ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

All dose groups demonstrated good safety and tolerability versus placebo, with similar adverse event (AE) incidence (70% vs. 85%). At the recommended Phase IIb dose (RP2D), the annualized rate of ...

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic ...

Mabwell Bioscience’s anti-ST2 monoclonal antibody (mAb) has led to a 40% reduction in annualised severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) In the randomised, ...